Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

P3 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso) for the Treatment of Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

Next Previous
X
Search
Trial Profile

P3 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso) for the Treatment of Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sufentanil (Primary)
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors AcelRx Pharmaceuticals; Talphera

    • Most Recent Events

    • 09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc
    • 08 Mar 2018 According to an AcelRx Pharmaceuticals media release, the company intends to submit results from IAP312 study together with results of phase 3 studies (IAP309, IAP310 and IAP311) as part of resubmission of a New Drug Application to the FDA in the second quarter of 2018.
    • 01 Aug 2017 According to an AcelRx Pharmaceuticals media release, the company intends to submit results from IAP312 study together with results of phase 3 studies (IAP309, IAP310 and IAP311) as part of resubmission of a New Drug Application to the FDA by the end of 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top